The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most ...

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

Learn more about lenacapavir, the most effective HIV treatment and prevention drug, and how its cost could cause a setback.

The U.S. has just approved a powerful new weapon in the fight against HIV: a twice-a-year prevention shot called Yeztugo. Made by Gilead Sciences, the injectable treatment slashes the risk […] The ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

In a recent decision, the Centers for Disease Control and Prevention (CDC) abruptly eliminated $200,000 in annual HIV ...

Despite the advancements in care, the most recent CDC HIV Surveillance report shows the Orlando-Kissimmee-Sanford area ranks in the Top 5 in the country, per capita, for HIV diagnoses. Dr ...

A core role of the CDC is to provide health surveillance and identify communities who are most at risk for HIV, as well as engage people who have HIV “but have been out of care” and lead them ...